



HAL
open science

Effect of Magnesium Sulfate on Mitochondrial Oxygen Consumption Rate In vitro Study

Amna Al Zaabi, Aiman Al Rahmani

► **To cite this version:**

Amna Al Zaabi, Aiman Al Rahmani. Effect of Magnesium Sulfate on Mitochondrial Oxygen Consumption Rate In vitro Study. *Journal of Bioanalysis & Biomedicine*, 2018, 10, 10.4172/1948-593x.1000206 . hal-04034143

HAL Id: hal-04034143

<https://hal.science/hal-04034143>

Submitted on 17 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Effect of Magnesium Sulfate on Mitochondrial Oxygen Consumption Rate *In vitro* Study

Amna Al Zaabi and Aiman Al-Rahmani*

Department of Pediatrics, Tawam Hospital, Al Ain, United Arab Emirates

Abstract

Hypoxic insults initiate a cascade of biochemical events that result in irreversible neuronal damage. Magnesium sulfate agent has a possible neuroprotective effect as it can work at different stages of hypoxic brain injury.

Objectives: Magnesium sulfate is used in the neonatal management of HIE as an adjunct medication to reduce Hypoxic Neuronal injury. In this *Vitro* study, we aimed to examine the efficacy of using magnesium sulfate in human cells to reduce oxygen consumption. We used *in-vitro* method utilizing foreskin as human cell surrogate.

Method: Foreskin specimens from healthy newborns were collected immediately after circumcision and processed within 1 h for measuring the cellular rate of O₂ consumption. Samples were placed in the oxygen phosphorescence analyzer and allowed to run for approximately 1 h. Injection then added magnesium sulfate at different doses into the vial. We analyze the O₂ consumption in the samples at different levels of Magnesium Sulfate; the results were plotted using Kaleida Graph TM software.

Results: The rate of respiration reduced with increasing the dose of MgSO₄. The Cumulative analysis of cellular respiration rate was before and after an addition of MgSO₄. Collectively yielding a (k) value of 0.08 μM O₂/min μM O₂ min⁻¹ mg- and 0.04 M O₂/min μM O₂ min⁻¹ mg- respectively with a significant P-value of <0.001.

Conclusion: Magnesium sulfate reduces the rate of O₂ Consumption in a dose-dependent manner.

Keywords: O₂ Consumption; Cellular respiration; Bioenergetics; Metabolism; Mitochondrial; Magnesium sulfate; Perinatal asphyxia; Neonates

Abbreviations: Pd phosphor: Pd (II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin; PBS: Phosphate-buffered saline; 1/τ: Phosphorescence Decay Rate; k_q: The Second-order O₂ Quenching Rate Constant in sec⁻¹ μM⁻¹; k: Rate of Cellular Respiration (μM O₂ min⁻¹); k_c: Rate of Cellular Respiration Corrected by Specimen Weight (μM O₂ min⁻¹ mg⁻¹); MgSO₄: Magnesium Sulfate.

Background

Brain Injury in Neonates can commonly be the result of perinatal hypoxic-ischemic encephalopathy (HIE), which may lead to significant morbidity or death in the newborn period. The injury to the brain occurs as a result of a combination of systemic hypoxemia; which refers to a compromised arterial oxygen concentration. In addition to a diminished cerebra [1] perfusion that leads to ischemia or insufficient blood flow to the cells to maintain their normal function. The pathogenesis of HIE is an integral sequence of cerebral insults that occur initially with hypoxemia, ischemia and next by oxygenation and reperfusion of the ischemic tissue. Perinatal hypoxia is multi-system organ damage with significant impairments in clotting, renal, and cardiac functions. Magnesium Neuroprotection properties are the results of blocking N-methyl-D-aspartate (NMDA) receptor-mediated calcium entry into the cell. Suppress the release of a neurotransmitter that activated by hypoxia [2] and modulating the actions of pro-inflammatory cytokines and oxygen free radicals.

Antenatal magnesium sulfate is one of the known strategies to reduce perinatal cerebral injury and act as Neuroprotection via several pathways [3,4]. Postnatal MgSO₄ treatment of severe perinatal asphyxia patients was shown in several studies to improve neurological outcomes at discharge for term neonates compared to control patients [5]. Meta-analysis of high quality randomizes studies demonstrate that the risk of

cerebral palsy is reduced to almost one-third in an infant who received antenatal magnesium sulfate [6].

Furthermore, providing Magnesium sulfate treatment was demonstrated to alter fetal cerebellar gene expression in response to hypoxia that known to contribute to cell death and neurogenesis [7]. These changes negatively affected the newborns for that some studies failed to prove the Neuroprotective effect of MgSO₄, which may be due to the dual reaction to the MgSO₄ treatment in observations reported for affected newborns [8]. The goal was to conduct *in vitro* study to investigate the effect of magnesium sulfate on metabolic rate and oxygen consumption in human cells using foreskin as a surrogate biomarker for metabolic rate [9-12].

Methods

Reagents and solutions

Pd (II) complex of meso-tetra-(4-sulfonatophenyl)-tetra benzoporphyrin (Pd phosphor) obtained from Porphyrin Products (Logan, UT). Minimum Essential Medium (MEM Alpha Modification) was purchased from Gibco (labeled as MEM). Phosphate-buffered saline (PBS), glucose oxidase (powder from *Aspergillus niger*), D (+) glucose anhydrous and remaining reagents were purchased from Sigma-Tau Pharmaceuticals (Gaithersburg, MD, USA).

*Corresponding author: Aiman Al-Rahmani, Department of Pediatrics, Tawam Hospital, Al Ain, United Arab Emirates, Tel: +97137677435; E-mail: arahmani@seha.ae

Received March 20, 2018; Accepted April 13, 2018; Published April 20, 2018

Citation: Al Zaabi A, Al-Rahmani A (2018) Effect of Magnesium Sulfate on Mitochondrial Oxygen Consumption Rate *In vitro* Study. J Bioanal Biomed 10: 60-63. doi:10.4172/1948-593X.1000206

Copyright: © 2018 Al Zaabi A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The Pd phosphor solution (2.5 mg/mL = 2 mM) was made in dH₂O and stored at -20°C in small aliquots. the pH was adjusted to ~7.0 with 12 N HCl and stored at -20°C. PBS with and without 5 mM glucose stored at 4°C. Cellular respiration measured in 1 mL sealed vials containing PBS (with and without 5 mM glucose), 3 μM Pd phosphor, and 0.5% fat-free albumin.

Foreskin specimens

Sample collection from participants was approved by the Al Ain Medical District Human Research Ethics Committee (Protocol No. 11/59, approved on 16 April 2012; “The phosphorescence oxygen analyzer as a screening tool for metabolic disorders”). Informed consent obtained from each patient.

Oxygen instrument

The rate of cellular respiration was determined using phosphorescence analyzer that measures the concentration of dissolved O₂ as a function of time [13,14]. The Pd phosphor had a maximum absorption at 625 nm and a maximum phosphorescence emission at 800 nm.

The samples exposed to light flashes (10 per sec) from a pulsed light-emitting diode array that peaked at 625 nm. Emitted phosphorescent light was filtered at 800 nm and detected by Hamamatsu photomultiplier tube. Amplified phosphorescence was digitized at 1-2 MHz using an analogue/digital converter (PCI-DAS 4020/12 I/O Board) with 1 to 20 MHz outputs. Pulses captured at 1.0 MHz [13].

The phosphorescence decay rate characterized by a single exponential; $I = I_0 e^{-t/\tau}$, where $I =$ Pd phosphor phosphorescence intensity. The values of $1/\tau$ were linear with dissolved O₂: $k_q [O_2]$, where $1/\tau =$ the phosphorescence decay rate in the presence of O₂, $1/\tau^0 =$ the phosphorescence decay rate in the absence of O₂, and $k_q =$ the second-order O₂ quenching rate constant in $sec^{-1} \mu M^{-1}$ [14].

Cellular respiration measured in 1 mL vials sealed from air. The vials contained PBS (with and without 5mM glucose), 3 μM Pd phosphor, and 0.5% fat-free albumin. The temperature was controlled by a circulating water bath (Precision ± 0.5°C). O₂ concentration, calculated using the equation: $k_q [O_2]$ [14], decreased linearly with time, indicating the kinetics of mitochondrial O₂ consumption was zero-order. The rate of respiration (k , in $\mu M O_2/min$) was, thus, the negative of the slope $d[O_2]/dt$. A program was developed using Microsoft Visual Basic 6, Microsoft Access Database 2007, and Universal Library components [13]. Magnesium sulfate injected into the vials at 60 min of respiration at different doses of 10 μg, 5 μg and 2.5 μg (stock conc. 50 mg/ml).

Statistical analysis

Data were analyzed using SPSS statistical package (version 19). The nonparametric test (2 independent variables) Mann-Whitney was used to compare treated and untreated sample.

Results

Our study demonstrates a dose dependent reduction of cellular Respiratory rate with the addition of Magnesium Sulfate (Figure 1A-C).

We compared the slope of cellular respiration at base line and then after adding Magnesium sulfate at increasing dosages (5 and 10 μM respectively).


We demonstrated a significantly reduced slope of cellular respiration with increasing dose of Mg Sulfate ($P < 0.001$, for both 5 μM and 10 μM in comparisson to baseline) (Figure 2).



Discussion

Magnesium Sulfate (MgSO₄) when given to mother 24 h prior to the delivery of a preterm infant, was reported to reduce mortality in addition to a favorable effect of improving neurological outcome, reduces gross motor dysfunction evident a 2 years evaluation [15].

A major research challenge remains, that is to develop effective methods to limit or prevent perinatal neuronal damage and reduce the severity or prevalence of cerebral palsy and associated co-morbidities following preterm births, and in infants who are exposed to a Hypoxic ischemic insult in the perinatal period [4].

There is increasingly encouraging evidence that MgSO₄ is neuroprotective in mature rat pups when given after experimental focal





stroke lesions with an effect that is dose dependent, and a response proven to be more neuroprotective in higher doses of $MgSO_4$.

There are no published studies in human subjects evaluating the combined efficacy of therapeutic hypothermia in the treatment of Hypoxic ischemic encephalopathy (HIE) in the neonatal period. As Therapeutic Hypothermia is emerging as a standard of care treatment for neonatal HIE (NRP reference), the added benefits of magnesium Sulfate in perinatal Hypoxic ischemic insult was not studied [16]. There are animal studies that evaluated neuronal injury reduction with

$MgSO_4$ in adult rats, where pre-treatment with $MgSO_4$ before global cerebral ischemia [17], combined with mild spontaneous hypothermia after ischemia, reduced hippocampal neuronal loss more than $MgSO_4$ or hypothermia alone [18]. Thus, combination therapy is promising, but it has not yet been tested in neonatal HIE. One multicenter clinical trial studying the safety and efficacy of hypothermia with $MgSO_4$ (Mag Cool) is currently listed on Clinical Trials Gov. [16].

The results of this study demonstrated a significant ($P < 0.01$) reduction in foreskin cellular respiration (as a cellular surrogate for the neonatal living cells) with an addition of $MgSO_4$. This effect of $MgSO_4$ was dose dependent whereas the concentration of $MgSO_4$ increased in the studied tissue, the cellular respiration (as reflected by oxygen consumption) decreased by 50% from the cellular respiration baseline in tissue samples, which were not treated with $MgSO_4$ [19].

The major limitation of this study was the inability unable to run same samples of the foreskin with different drug concentration due to limited cellular viability over a short period. Therefore an alternative approach was followed utilizing one concentration of $MgSO_4$ for each set of sample, then to compare the cellular respiration mean values of each group of samples to the other groups which were treated with different doses.

The results of this novel *in vitro* study in human cells may indicate that infants who are exposed to treatment with $MgSO_4$ may have similar systemic and cerebral hemodynamics; nevertheless, the Neuroprotection properties of $MgSO_4$ are exerted by lowering the cerebral fractional tissue oxygen extraction cFTOE compared to non-treated controls. These findings also suggest that similar reduction in cerebral metabolism may be a component of the neuroprotective action of antenatal administered $MgSO_4$ [20].

We previously reported a similar experimental method studying neonatal foreskin cellular respiration. Demonstrating that neonatal cellular respiration is highly sensitive to critical temperatures ($33^\circ C$ vs. $35^\circ C$) [1].

References

- Al Zaabi A, Rahmani AY, Souid A (2014) Optimal temperature for whole-body hypothermia in the newborn: an *in vitro* study using foreskin mitochondrial oxygen consumption. *J Neonatal Perinatal Med* 7: 179-183.
- Gathwala G, Khera A, Singh J, Balhara B (2010) Magnesium for neuroprotection in birth asphyxia. *J Pediatr Neurosci* 5: 102-104.
- Cetinkaya M, Alkan T, Ozyener F, Kafa IM, Kurt MA, et al. (2011) Possible neuroprotective effects of magnesium sulfate and melatonin as both pre- and post-treatment in a neonatal hypoxic-ischemic rat model. *Neonatology* 99: 302-310.
- Khashaba MT, Shouman BO, Shaltout AA, Al-Marsafawy HM, Abdel-Aziz MM, et al. (2006) Excitatory amino acids and magnesium sulfate in neonatal asphyxia. *Brain Dev* 28: 375-379.
- Bhat MA, Charoo BA, Bhat JI, Ahmad SM, Ali SW, et al. (2009) Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial. *Pediatrics* 123: e764-e769.
- McIntyre S, Novak I, Cusick A (2010) Consensus research priorities for cerebral palsy: a Delphi survey of consumers, researchers, and clinicians. *Dev Med Child Neurol* 52: 270-275.
- Shokry M, Elsedfy GO, Bassiouny MM, Anmin M, Abozid H (2010) Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns. *Acta Obstet Gynecol Scand* 89: 801-806.
- Haramati O, Mane R, Molczadzki G, Perez-Polo JR, Chalifa-Caspi V, et al. (2010) Magnesium sulfate treatment alters fetal cerebellar gene expression responses to hypoxia. *Int J Dev Neurosci* 28: 207-216.
- Oddie S, Tuffnell DJ, McGuire W (2015) Antenatal magnesium sulfate: Neuro-protection for preterm infants. *Arch Dis Child Fetal Neonatal Ed* 100: F553-F557.

10. Groenendaal F, Rademaker CM, Toet MC, de Vries LS (2002) Effects of magnesium sulphate on amplitude-integrated continuous EEG in asphyxiated term neonates. *Acta Paediatr* 91: 1073-1077.
11. Al-Jasmi F, Pramathan T, Swid A, Sahari B, Penefsky HS (2013) Mitochondrial oxygen consumption by foreskins and fibroblasts. *Sultan Qaboos Univ Med J* 13: 411-416.
12. Al-Jasmi F, Penefsky HS, Souid AK (2003) The phosphorescence oxygen analyzer as a screening tool for disorders with impaired lymphocyte bioenergetics. *Mol Genet Metab* 104: 529-536.
13. Shaban S, Marzouqi F, Al Mansouri A, Penefsky HS, Souid AK (2010) Oxygen measurements via phosphorescence. *Comput Methods Programs Biomed* 100: 265-268.
14. Lo LW, Koch CJ, Wilson DF (1996) Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: a phosphor with general application for measuring oxygen concentration in biological systems. *Anal Biochem* 236: 153-160.
15. Crowther CA, Hiller JE, Doyle LW, Haslam RR (2003) Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. *JAMA* 290: 2669-2676.
16. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE (1996) Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. *J Neurosurg* 85: 117-124.
17. Galinsky R, Bennet L, Groenendaal F, Lear CA, Tan S, et al. (2014) Magnesium Is Not Consistently Neuroprotective for Perinatal Hypoxia-Ischemia in Term-Equivalent Models in Preclinical Studies: A Systematic Review. *Dev Neurosci* 36: 73-82.
18. Zhu H, Meloni BP, Moore SR, Majda BT, Knuckey NW (2004) Intravenous administration of magnesium is only neuroprotective following transient global ischemia when present with post-ischemic mild hypothermia. *Brain Res* 1014: 53-60.
19. Zhu H, Meloni BP, Bojarski C, Knuckey MW, Knuckey NW (2015) Post-ischemic modest hypothermia (35 degrees C) combined with intravenous magnesium is more effective at reducing CA1 neuronal death than either treatment used alone following global cerebral ischemia in rats. *Exp Neurol* 193: 361-368.
20. Stark MJ, Hodyl NA, Andersen CC (2015) Effects of antenatal magnesium sulfate treatment for neonatal neuro-protection on cerebral oxygen kinetics. *Pediatr Res* 78: 310-314.